FURUNO-ELECTRIC
20.8.2024 06:01:33 CEST | Business Wire | Press release
Furuno Electric is delighted to announce that the company will participate in Jammertest 2024 in Andøya, Norway from 9 to 13 September.
The participants will test GNSS receivers in an environment where they will actually be exposed to jamming and spoofing* signals and obtain data on their tolerance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819796325/en/
Jammertest 2024 (Graphic: Business Wire)
About Jammertest
This Jammertest is the world's largest test event where resistance to jamming and spoofing can be tested in a real environment. It is organized by the Norwegian Public Roads Administration, Norwegian Communications Authority, Norwegian Defence Research Establishment, Norwegian Metrology Service, Norwegian Space Agency and Testnor.
Jamming has actually been detected in the Black Sea, Northern Europe, and the Middle East, and there is a growing need for enhanced resiliency in critical infrastructure such as traffic control and mobile communications. Furuno has been testing its receivers by creating signals that simulate jamming and spoofing in a lab environment, but to verify and improve our anti-jamming capabilities, it is ideal to perform a variety of evaluations in a real environment. To allow participating companies and institutions to test their GNSS receiver-equipped products in a real-world environment, the organizer will conduct various types of jamming and spoofing attacks during the event.
The resistance test Furuno will carry out
In this Jammertest, Furuno will test the jamming and spoofing resistance of GT-100 which is Furuno’s timing multi-GNSS receiver module that supports dual-frequency band reception in the L1 and L5 bands. GNSS receivers for time synchronization are used in critical infrastructures that require robustness, such as 5G mobile base stations, TV broadcasting, financial institutions, and power grids. The latest product, GT-100, can automatically mitigate the effects of jamming and spoofing signals while providing users with real-time notification of the jamming signal frequency and signal strength. Also, if it completely loses reception of the L1 band signal, it can still maintain reception of the L5 band signal and continuously output stable time.
By participating in the Jammertest 2024, Furuno will evaluate and analyze the level of resistance of GT-100 to jamming and spoofing in real-world environments and use the results to further improve its robustness.
About Jammertest 2024
Official name of the event: Jammertest 2024
Event dates: September 9 - 13, 2024
Location: Andøya, Norway
Official website: https://jammertest.no/jammertest/
Products Tested
Timing Multi-GNSS Receiver Module GT-100
https://www.furuno.com/en/products/gnss-module/GT-100
Multi-GNSS Timing Antennas AU-500
https://www.furuno.com/en/products/gnss-antenna/AU-500
* Jamming and Spoofing: Jamming means radio waves that interfere with GNSS signals. Spoofing means that malicious actors intentionally mimic and broadcast GNSS-like signals with the intent to trick nearby GNSS receivers into calculating incorrect position and/or time.
Related Links
Announced on May 16, 2023: Furuno Announces High-Performance Multi-GNSS Timing Antennas
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1320&dispmid=961
Announced on September 14, 2022: Furuno Announces Most Advanced Global Timing Solutions Supporting L1 and L5 GNSS Signals
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1216&dispmid=961
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819796325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom